Early research (Phase 1)Study completedNCT03269071What this trial is testingNeural Stem Cell Transplantation in Multiple Sclerosis PatientsWho this might be right forProgressive Multiple Sclerosis IRCCS San Raffaele 4
Testing effectiveness (Phase 2)Study completedNCT03423121What this trial is testingA Trial of Bile Acid Supplementation in Patients With Multiple SclerosisWho this might be right forProgressive Multiple Sclerosis Johns Hopkins University 59
Testing effectiveness (Phase 2)Study completedNCT01450488What this trial is testingMasitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisWho this might be right forMultiple Sclerosis AB Science 35
Early research (Phase 1)UnknownNCT02903537What this trial is testingTolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)Who this might be right forMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive Fundació Institut Germans Trias i Pujol 16
Not applicableStudy completedNCT04545372What this trial is testingAerobic Exercises for Multiple SclerosisWho this might be right forMultiple Sclerosis, Primary Progressive South Valley University 30
Not applicableStudy completedNCT04593927What this trial is testingLong Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsWho this might be right forSecondary Progressive Multiple Sclerosis (SPMS) Novartis Pharmaceuticals 451
Very early researchNot Yet RecruitingNCT07583030What this trial is testingA Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune DiseasesWho this might be right forRelapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)Progressive Multiple Sclerosis (PMS)+1 more Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 44
Testing effectiveness (Phase 2)Ended earlyNCT03283826What this trial is testingPhase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisWho this might be right forPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis Atara Biotherapeutics 134
Testing effectiveness (Phase 2)Looking for participantsNCT07282574What this trial is testingEvaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)Who this might be right forProgressive Multiple Sclerosis Hoffmann-La Roche 360
Not applicableUnknownNCT06485115What this trial is testingTelerehabilitation in Progressive Multiple SclerosisWho this might be right forProgressive Multiple Sclerosis Universita di Verona 78
Not applicableStudy completedNCT01235455What this trial is testingPortuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectorsWho this might be right forRelapsing Remitting Multiple Sclerosis (RRMS)Secondary Progressive Multiple Sclerosis (SPMS) Bayer 10
Not applicableStudy completedNCT03302806What this trial is testingStudy to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple SclerosisWho this might be right forProgressive Multiple Sclerosis Nantes University Hospital 103
Post-approval studies (Phase 4)Looking for participantsNCT07609719What this trial is testingOcrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyWho this might be right forMultiple Sclerosis Genentech, Inc. 100
Not applicableLooking for participantsNCT07392879What this trial is testingBringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) PatientsWho this might be right forProgressive Multiple SclerosisDepression University of Michigan 40
Testing effectiveness (Phase 2)Looking for participantsNCT03109288What this trial is testingTargeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Who this might be right forMultiple Sclerosis National Institute of Allergy and Infectious Diseases (NIAID) 250
Testing effectiveness (Phase 2)UnknownNCT01228396What this trial is testingAIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple SclerosisWho this might be right forSecondary Progressive Multiple Sclerosis Daval International Limited 20
Not applicableStudy completedNCT07680738What this trial is testingTranscranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple SclerosisWho this might be right forMultiple Sclerosis, MSMultiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting+5 more Universidad de Almeria 38
Large-scale testing (Phase 3)Study completedNCT00869726What this trial is testingPatients With Secondary Progressive Multiple SclerosisWho this might be right forSecondary Progressive Multiple Sclerosis Eli Lilly and Company 596
Large-scale testing (Phase 3)Study completedNCT00799890What this trial is testingSunphenon in Progressive Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis Friedemann Paul 61
Large-scale testing (Phase 3)Study completedNCT03315923What this trial is testingComparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsWho this might be right forSecondary Progressive Multiple Sclerosis Isfahan University of Medical Sciences 84